Twist Bioscience Corporation

$69.22 ▼ -6.37%
2026-06-06 11:08:00

Explore Twist Bioscience Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.

Market Cap
$4.31 B
Current Price
$69.22
52W High / Low
$80.5 / $23.3
Stock P/E
Book Value
$7.8
Dividend Yield
ROCE
-24.75%
ROE
-17.46%
Face Value
EPS
$-1.33
Exp Qtr EPS
Sector
Healthcare

TWST — Monthly Price History

Adjusted close price  ·  Hover to see price & month

Pros

  • Balance sheet leverage appears manageable.
  • Short-term liquidity looks comfortable.
  • Valuation is not stretched on P/E basis.

Cons

  • Return on equity is on the weaker side.
  • Capital efficiency is modest.
  • Operating margin is thin.
  • Net margin is relatively low.

Sift Stocks

S.No. Name Price P.E. Market Cap Div Yld % ROCE ROE 52Week High/ Low Book Value
1. Thermo Fisher Scientific Inc. $472.8 25.75 $176.31 B 0.39% 8.52% 13.24% $643.99 / $385.46 $141.96
2. Danaher Corporation $184.3 35.52 $131.02 B 0.86% 6.12% 7.06% $242.8 / $160.93 $74.32
3. IDEXX Laboratories, Inc. $562.16 40.5 $44.36 B 61.76% 70.87% $769.98 / $506.91 $20.14
4. Agilent Technologies, Inc. $135.44 27.28 $38.58 B 0.74% 14.25% 20.84% $160.27 / $108.35 $23.82
5. Waters Corporation $365.36 83 $37.29 B 20.92% 8.04% $414.15 / $275.05 $43.01
6. Natera, Inc. $215.31 $31.25 B -15.84% -15.13% $256.36 / $131.81 $12.26
7. IQVIA Holdings Inc. $183.45 22.11 $30.62 B 10.59% 22.46% $247.05 / $146.44 $38.34

Quarterly Results

Figures shown in M / B

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Sales103.7 M99.01 M96.06 M92.79 M88.71 M
Operating Profit-33.1 M-29.93 M-30.12 M-41.56 M-34.64 M
Net Profit-30.51 M-27.14 M20.39 M-39.33 M-31.59 M
EPS in Rs-0.5-0.440.33-0.64-0.52

Profit & Loss

Figures shown in M / B

2025202420232022
Sales376.57 M312.97 M245.11 M203.56 M
Operating Profit-136.26 M-175.9 M-206.9 M-249.02 M
Net Profit-77.67 M-208.73 M-204.62 M-217.86 M
EPS in Rs-1.27-3.4-3.34-3.55

Balance Sheet

Figures shown in M / B

2025202420232022
Total Assets641.86 M614.32 M776.4 M961.38 M
Total Liabilities168.9 M141.63 M152.97 M171.99 M
Equity472.96 M472.69 M623.43 M789.38 M
Current Assets332.97 M346.78 M424.26 M596.48 M
Current Liabilities91.41 M71.01 M73.32 M90.66 M

Cash Flow

Last available yearly cash flow history

2025202420232022
Operating CF-47.63 M-64.09 M-142.47 M-124.39 M
Investing CF-24.76 M-3.07 M50.61 M-232.93 M
Financing CF28.54 M6.89 M0.91 M270.53 M
Free CF-75.63 M-69.17 M-170.25 M-226.24 M
Capex-28 M-5.08 M-27.78 M-101.86 M

5Y Margin & Growth History

Last 5 years of annual financial statement data.

2024202320222021
Revenue Growth %27.69%20.41%
Earnings Growth %-2.01%6.08%
Profit Margin %-66.69%-83.48%-107.02%
Operating Margin %-56.2%-84.41%-122.33%
Gross Margin %42.61%36.61%41.38%
EBITDA Margin %-46.16%-72.45%-103.99%

Dividend & Split History

Latest dividend payments and stock split events.

Dividend History

No dividend history available.

Stock Splits

No stock split history available.

Shareholding Pattern

Shares and value shown in M / B

Holder Name Type Shares Value % Out Report Date
ARK ETF Trust-ARK Innovation ETF Mutual Fund 4.19 M $210.51 M 0.07% 2026-01-31
ARK ETF Trust-ARK Genomic Revolution ETF Mutual Fund 2.23 M $111.92 M 0.04% 2026-01-31
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF Mutual Fund 1.97 M $99.15 M 0.03% 2026-01-31
iShares Trust-iShares Russell 2000 ETF Mutual Fund 1.42 M $71.4 M 0.02% 2026-01-31
Thrivent Mutual Funds-Thrivent Small Cap Stock Fund Mutual Fund 0.82 M $41.14 M 0.01% 2026-01-31
ARK Investment Management, LLC Institutional 7.56 M $379.56 M 0.12% 2025-12-31
William Blair Investment Management, LLC Institutional 5.95 M $298.97 M 0.1% 2025-12-31
Blackrock Inc. Institutional 5.89 M $295.99 M 0.1% 2025-12-31
Artisan Partners Limited Partnership Institutional 5.83 M $292.73 M 0.1% 2025-12-31
Vanguard Group Inc Institutional 5.78 M $290.02 M 0.09% 2025-12-31
Edgepoint Investment Group Inc. Institutional 5.38 M $270.03 M 0.09% 2025-12-31
State Street Corporation Institutional 3.63 M $182.15 M 0.06% 2025-12-31
Sumitomo Mitsui Trust Group, Inc. Institutional 1.9 M $95.54 M 0.03% 2025-12-31
Amova Asset Management Americas Inc Institutional 1.9 M $95.54 M 0.03% 2025-12-31
Soleus Capital Management, L.P. Institutional 1.86 M $93.48 M 0.03% 2025-12-31

Frequently Asked Questions — Twist Bioscience Corporation

Will Twist Bioscience Corporation stock hit $83 in 2026?

Twist Bioscience Corporation (TWST) is currently trading at $69.22, with a 52-week range of $23.3 to $80.5. Reaching the $83 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.

Wall Street analysts currently have a consensus price target of $55.0 for Twist Bioscience Corporation, with a Strong_buy rating, and the most bullish analysts see the stock reaching as high as $75.0. Whether Twist Bioscience Corporation can reach $83 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Healthcare space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.

Historically, TWST has delivered a -14.2% CAGR over the past 5 years, which suggests the stock has demonstrated meaningful long-term growth momentum. However, past performance does not guarantee future results, and short-term price movements can be influenced by macroeconomic shifts, interest rate changes, and investor sentiment. Use the TWST Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.

Is Twist Bioscience Corporation stock worth buying at $69.22?

Whether Twist Bioscience Corporation (TWST) is worth buying at $69.22 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:

Valuation: Valuation data is currently limited — check the full ratios section on StockSifting for the latest P/E, P/B, and EV/EBITDA figures.

Profitability & efficiency: Twist Bioscience Corporation has a Return on Capital Employed (ROCE) of -24.8%, which reflects modest capital efficiency. Its Return on Equity (ROE) stands at -17.5%.

Financial health: The Debt-to-Equity ratio of 24.79 indicates a higher degree of financial leverage — investors should monitor debt servicing capacity.

Analyst view: The Wall Street consensus recommendation for TWST is currently Strong_buy, with a mean price target of $55.0 based on 9 analyst ratings. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.

What is the analyst price target for Twist Bioscience Corporation (TWST) in 2026?

As of 2026, Wall Street analysts have set a consensus (mean) price target of $55.0 for Twist Bioscience Corporation (TWST), aggregated from 9 analyst ratings. The overall analyst recommendation is Strong_buy.

The price target range spans from $36.0 on the bearish end to $75.0 on the most optimistic projection, with a median target of $55.0. This wide range reflects differing views on Twist Bioscience Corporation's growth prospects, competitive positioning, and macroeconomic sensitivity.

It is important to note that analyst price targets are forward-looking estimates based on financial models, earnings projections, and sector assumptions — they are not guarantees. Targets are regularly revised following quarterly earnings results, management guidance updates, or shifts in the broader economic outlook. Stocks can trade significantly above or below analyst targets depending on market conditions. View the full analyst breakdown and track target revisions on the TWST analysis page on StockSifting.

What will Twist Bioscience Corporation stock be worth in 2029?

Projecting Twist Bioscience Corporation (TWST)'s stock price 3 years into the future — to 2029 — requires making assumptions about the company's earnings growth, valuation multiple, and broader market conditions. No projection is guaranteed, but historical growth rates offer a reasonable starting point.

Based on TWST's historical 5-year Compound Annual Growth Rate (CAGR) of -14.2%, if that rate of growth were to continue, the stock could reach approximately $44 by 2029 — up from its current price of $69.22. This projection assumes the historical CAGR holds, which depends on Twist Bioscience Corporation sustaining its revenue growth, maintaining profit margins, and the market continuing to reward it at a similar valuation multiple.

In reality, stock prices rarely follow a straight-line trajectory. Short-term volatility, earnings misses, sector rotations, interest rate changes, and macroeconomic events can all cause significant deviations from any modeled path. Investors with a 3-year horizon should focus on the fundamental business trajectory — revenue growth, expanding margins, and free cash flow generation — rather than short-term price fluctuations.

You can model different scenarios — conservative, base, and bull case — using the TWST Return Calculator on StockSifting. Enter any investment amount and CAGR assumption to see projected outcomes over your chosen time horizon. All projections are mathematical estimates only and do not constitute financial advice.